<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T01:19:05Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/8767" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/8767</identifier><datestamp>2026-09-24T01:50:45Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Richards, Carl D.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Botelho, Fernando M.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Molecular Immunology, Virology and Inflammation</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T16:43:54Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-06-18T16:43:54Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2011-03-05</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">1999-12</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/3944</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">4961</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">1852001</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/8767</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/23309</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>The progression of an inflammatory response is largely dictated by soluble&lt;br />factors termed cytokines reknown for their redundant and pleiotropic nature in&lt;br />modulation of both immune and stromal cells. Individual members of the&lt;br />interleukin-6 (IL-6)-type cytokine family possess both unique and shared biological&lt;br />activities. These cytokines may participate in tissue remodelling by promoting&lt;br />reconstruction ofextracellular matrix (ECM) following nonspecific tissue damage by&lt;br />inflammatory cells. Consistent with this view, these cytokines upregulate expression&lt;br />of an ECM protease inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1) and&lt;br />thus may alter net enzymatic degradation of ECM. The overall goal of this thesis&lt;br />is to examine mechanisms by which TIMP-1 is regulated by IL-6-type cytokines,&lt;br />especially by the cytokine oncostatin M (OSM). The promoter of TIMP-1 has&lt;br />therefore been studied in detail to address the mechanisms by which OSM (and IL-6&lt;br />type cytokines) regulate the transcription of the TIMP-1 gene. The approaches&lt;br />undertaken have included deletion analysis of the TIMP-1 gene nucleotide&lt;br />sequences proximal to the start of transcription to define DNA sequences&lt;br />necessary/sufficient for cytokine-induced TIMP-1 promoter activity. In addition, the&lt;br />binding of nuclear factors to these DNA elements and cytokine-response elements, their expression and involvement in the regulation of TIMP-1 transcription have been explored.&lt;/p> &lt;p>We have identified sequences proximal to the start of TIMP-1 transcription&lt;br />that are necessary for maximal responsiveness to OSM and IL-6. Deletion analysis&lt;br />of the proximal TIMP-1 promoter (-95 to +47 TIMP-1 sequences) has identified a&lt;br />nucleotide sequence within -59 to -53 ofthe murine TIMP-1 promoter that harbours&lt;br />an AP-1 consensus DNA binding element. This element is necessary for maximal&lt;br />OSM or IL-6 induced promoter activity of TIMP1-CAT reporter gene constructs&lt;br />transfected into human hepatoma HepG2 cells. OSM is the most potent stimulus&lt;br />(approx. 11-fold for OSM, and 4-fold for IL-6) of this response and additional&lt;br />sequences 3-prime to +1 ofthe TIMP-1 gene are also necessary for maximal OSM&lt;br />responsiveness.&lt;/p> &lt;p>Electrophoretic mobility shift assays demonstrated two gel-shifted complexes&lt;br />which bind the TIMP-1 AP-1 site. An AP-1 gel-shifted complex is present in the&lt;br />absence of cytokine stimulation ("complex 1"), while OSM and not other IL-6-type&lt;br />cytokines, stimulated the formation of a second AP-1 gel shifted complex.&lt;br />Nuclear factors binding to TIMP-1 AP-1 complex 1 include junB, junD and fosrelated&lt;br />antigens. However, unlike complex1, c-fos is present and necessary for the&lt;br />formation of the OSM-induced TIMP-1 AP-1 complex2. Consistent with this, OSM&lt;br />is a potent inducerofc-fos protein expression among IL-6-type cytokines. Both the&lt;br />formation of complex2 and c-fos expression require new protein synthesis. JunB&lt;br />and junO are constitutively expressed, while the expression of fos-related antigens are induced in response to OSM. In addition, although PMA was also a potent&lt;br />inducer of c-fos expression, induction of TIMP-1 promoter activity by the&lt;br />combination of PMA and IL-6 was comparable to IL-6 alone and did not equal the&lt;br />significantly higher induction by OSM. Within the same cells, OSM and IL-6 equally&lt;br />induced STATDNA-binding activity. An Ets-consensus site (nucleotides -45 to -40)&lt;br />flanking the 3-prime end of the AP-1 site is a weak binding site for Ets-related&lt;br />nuclear factors, and an SP-1 site near +1 (-11 to -6) is a strong binding siteforSP1&lt;br />nuclear factors and related SP-1 site binding proteins. No STAT nuclear factor&lt;br />binding to the proximal TIMP-1 promoterwas detected. Taken together, the TIMP1&lt;br />AP-1 site and c-fos represent a unique target of OSM signalling and activation of&lt;br />AP-1 complexes (possibly containing c-fos) by OSM as well as sequences&lt;br />downstream of TIMP-1 +1 contribute to maximal responsiveness of the promoter&lt;br />to this cytokine among IL-6 family members.&lt;/p> &lt;p>The contribution of c-fos to OSM-induced TIMP-1 expression was further&lt;br />explored in murine cells. OSM stimulates the expression of c-fos and activates&lt;br />STATs 1, 3 and 5 DNA-binding activity in murine fibroblasts. As observed in&lt;br />human cells, OSM but not other IL-6-type cytokines upregulated c-fos expression&lt;br />which participated in complexes binding the TIMP-1 AP-1 site. OSM was also&lt;br />unique among IL-6 family members in activating STAT5 DNA-binding activity in&lt;br />murine fibroblasts. However, in contrast to observations in human HepG2 cells,&lt;br />deletion analysis of the TIMP-1 promoter showed that the AP-1 site (-59/-53) was&lt;br />v not necessary for OSM-mediated upregulation of the TIMP-1 proximal promoter&lt;br />activity over basal levels in murine NIH3T3 fibroblasts and co-transfection of a&lt;br />dominant-negative of AP-1 had no effect. However, transfection of dominant-negative&lt;br />STATs1, 3 or5 (especially STAT3) could diminish cytokine-induced TIMP1&lt;br />promoter activity. In addition, c-Fos was dispensable for OSM-mediated&lt;br />upregulation ofTIMP-1 mRNA levels as TIMP-1 expression was detected in wildtype&lt;br />and c-fos knockout murine lung fibroblasts. Consistent with deletion analysis&lt;br />ofthe TIMP-1 promoter in human cells, dominant-negative AP-1 expression vectors&lt;br />abrogated OSM-mediated TIMP-1 promoter activity, while Stat-dominant negative&lt;br />expression vectors did not. Taken together, the examination of murine and human&lt;br />systems suggests that AP-1 and STAT nuclear factors can contribute to the&lt;br />regulation of the TIMP-1 promoter.&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Immunology and Infectious Disease</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Immunology and Infectious Disease</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Oncostatin M Regulation of the Tissue Inhibitor of Matrix Metalloproteinases-1 Promoter</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>